Keyphrases
Negative Allosteric Modulator
95%
Metabotropic Glutamate Receptor 5 (mGluR5)
69%
MGlu
28%
Positive Allosteric Modulator
26%
Small Molecule Inhibitors
24%
Tool Compound
23%
Potassium Channel
21%
Structure-activity Relationship
20%
Chemotype
20%
Small Molecules
20%
Penetrant
20%
Metabotropic Glutamate Receptor
18%
Allosteric Modulator
17%
MGlu5 NAM
15%
Polo-like Kinase 1 (PLK1)
13%
Carboxamide
13%
Patent Review
13%
Relationship Research
13%
Ether
13%
Ring-closing Metathesis
13%
Central Nervous System
12%
MGlu3
12%
MGlu1
12%
Mouse Model
12%
MGlu2
12%
Picolinamide
11%
Medium-sized Rings
11%
New Series
11%
Thiophene
10%
High-throughput Screening
10%
Total Synthesis
10%
Aldehyde Oxidase
10%
Brevetoxin
10%
Epilepsy of Infancy with Migrating Focal Seizures (EIMFS)
10%
Disubstituted
9%
Cell-based
9%
Glutamate Receptors
9%
Highly Selective
9%
Asymmetric Allylic Alkylation
8%
CNS Exposure
8%
Enantioselective Synthesis
8%
Glycolate
8%
Rodents
8%
Gain-of-function mutation
8%
Potential Therapeutics
8%
Group II Metabotropic Glutamate Receptors
8%
Structure-activity Relationship Studies
8%
Potent Inhibitor
8%
KCNT1
8%
CNS Penetration
7%
Pharmacology, Toxicology and Pharmaceutical Science
Allosteric Modulator
100%
Metabotropic Receptor
41%
Structure Activity Relationship
32%
Potassium Channel
26%
Positive Allosteric Modulator
23%
Receptor
21%
Glutamate Receptor
18%
Focal Epilepsy
16%
Carboxamide
14%
Metabotropic Receptor 5
13%
Pharmacokinetics
12%
Mouse Model
12%
Diseases
11%
Protein Binding
11%
Competitive Antagonist
10%
Benign Childhood Epilepsy
10%
Clinical Trial
8%
Picolinamide
8%
Binding Site
7%
Aldehyde Oxidase
6%
Polo Like Kinase 1
6%
Cytochrome P450
6%
Xanthine
6%
IC50
6%
Somatomedin C Receptor
6%
Pyrimidine
6%
Parkinson's Disease
6%
G Protein Coupled Receptor
6%
Anxiolytic
5%
Pyrazine
5%
